Skip to main content
Evidence Snapshot

Mineralocorticoid receptor

CHEMBL1994 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T17:04:24Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1994
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Mineralocorticoid receptor as ChEMBL target CHEMBL1994, mapped to UniProt P08235. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Mineralocorticoid receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1994
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P08235
Mineralocorticoid receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Mineralocorticoid receptor matters

As of 2026-09-13

Mineralocorticoid receptor is reviewed as Mineralocorticoid receptor (UniProt P08235); Mineralocorticoid receptor shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block.; 8 linked drugs keep this evidence frame grounded.; the current evidence base includes 23 approved drugs, 1446 compounds, and 276 assays, with lead potency reaching pChEMBL 10.3.

Disease context
cardiovascular disease

Mineralocorticoid receptor shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block. 8 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BALCINRENONE, CANRENOATE POTASSIUM, CANRENONE.

Start review with cardiovascular disease because it currently carries approved-linked support. Linked drugs include BALCINRENONE, CANRENOATE POTASSIUM, CANRENONE, EPLERENONE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 8 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 23 approved drugs, 1446 compounds, and 276 assays for this target. The dominant activity type is IC50. CHEMBL4532472 is the current potency anchor at pChEMBL 10.3.

Use CHEMBL4532472 as the tractability anchor when discussing potency (pChEMBL 10.3).

Activity source · ChEMBL 36 via Core Engine
23 approved pChEMBL 10.3
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Mineralocorticoid receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P08235, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why cardiovascular disease is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1446
Total Compounds
276
Total Assays
23
Approved Drugs
IC50: 1289.0, KI: 276.0, EC50: 86.0, KD: 7.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4532472
 10.3 EC50 —
No preferred name
CHEMBL4095917
 10.1 Ki —
No preferred name
CHEMBL273453
 9.7 EC50 Clinical
No preferred name
CHEMBL4086416
 9.6 Ki —
No preferred name
CHEMBL131
 9.5 Ki Approved

Approved Drugs

Structure Compound First Approval
FINERENONE
CHEMBL2181927
 2021
FLUTICASONE FUROATE
CHEMBL1676
 2007
EPLERENONE
CHEMBL1095097
 2002
MIFEPRISTONE
CHEMBL1276308
 2000
BUDESONIDE
CHEMBL1370
 1994
FLUTICASONE PROPIONATE
CHEMBL1473
 1990
HYDROCORTISONE BUTYRATE
CHEMBL1683
 1982
PROGESTERONE
CHEMBL103
 1976
SPIRONOLACTONE
CHEMBL1393
 1960
DEXAMETHASONE
CHEMBL384467
 1958
PREDNISOLONE
CHEMBL131
 1955
HYDROCORTISONE
CHEMBL389621
 1952
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T17:04:24Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1994